TW201341387A - 芳基醚結構之激酶抑制劑 - Google Patents

芳基醚結構之激酶抑制劑 Download PDF

Info

Publication number
TW201341387A
TW201341387A TW102108352A TW102108352A TW201341387A TW 201341387 A TW201341387 A TW 201341387A TW 102108352 A TW102108352 A TW 102108352A TW 102108352 A TW102108352 A TW 102108352A TW 201341387 A TW201341387 A TW 201341387A
Authority
TW
Taiwan
Prior art keywords
pyridin
mmol
amine
group
methyl
Prior art date
Application number
TW102108352A
Other languages
English (en)
Chinese (zh)
Inventor
菲佛卡南達Ｍ 福魯赫拉
潘森梁
羅庫瑪 雷賈曼恩
約翰Ｅ 馬可
瓊安Ｊ 布朗森
卡洛琳 戴安 德茲爾巴
瑟斯希爾 傑森安德 那拉
瑪希斯瓦倫 希法沙賓 卡拉索魯胡
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201341387A publication Critical patent/TW201341387A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW102108352A 2012-03-09 2013-03-08 芳基醚結構之激酶抑制劑 TW201341387A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608737P 2012-03-09 2012-03-09

Publications (1)

Publication Number Publication Date
TW201341387A true TW201341387A (zh) 2013-10-16

Family

ID=47892007

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102108352A TW201341387A (zh) 2012-03-09 2013-03-08 芳基醚結構之激酶抑制劑

Country Status (11)

Country Link
US (2) US8703953B2 (https=)
EP (1) EP2822952B1 (https=)
JP (1) JP2015510881A (https=)
CN (1) CN104144932A (https=)
AR (1) AR090293A1 (https=)
CA (1) CA2866671A1 (https=)
EA (1) EA201491647A1 (https=)
MX (1) MX2014010684A (https=)
TW (1) TW201341387A (https=)
UY (1) UY34666A (https=)
WO (1) WO2013134036A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
US9914740B2 (en) 2013-07-02 2018-03-13 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
EP3044226B1 (en) * 2013-09-11 2017-09-06 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
WO2015054358A1 (en) 2013-10-11 2015-04-16 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP6276865B2 (ja) * 2014-01-29 2018-02-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アリールラクタムキナーゼ阻害剤
ES2701903T3 (es) * 2014-01-31 2019-02-26 Bristol Myers Squibb Co Inhibidores de cinasa a base de quinolina
SMT201800665T1 (it) 2014-04-02 2019-01-11 Bristol Myers Squibb Co Inibitori biarilici di chinasi
ES2740224T3 (es) 2015-04-10 2020-02-05 Bristol Myers Squibb Co 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
BR112017019207A2 (pt) * 2015-05-22 2018-04-24 Dow Agrosciences Llc recuperação e/ou reutilização de catalisador de paládio após acoplamento de suzuki
JP6864674B2 (ja) * 2015-10-01 2021-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ビアリールキナーゼ阻害剤
WO2017059085A1 (en) * 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
SG10202009148XA (en) 2016-12-15 2020-10-29 Hoffmann La Roche Process for preparing btk inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
AU2003230772A1 (en) 2002-04-05 2003-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Cyanamides useful as reversible inhibitors of cysteine proteases
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004072018A1 (ja) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited アミン誘導体
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US20050288338A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
JP2007217408A (ja) 2006-01-19 2007-08-30 Tanabe Seiyaku Co Ltd 医薬組成物
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20080039535A1 (en) 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treating neurological disorders
US20100183514A1 (en) * 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88

Also Published As

Publication number Publication date
JP2015510881A (ja) 2015-04-13
US8969564B2 (en) 2015-03-03
AR090293A1 (es) 2014-11-05
US20140179725A1 (en) 2014-06-26
EP2822952B1 (en) 2016-04-06
US20130237555A1 (en) 2013-09-12
CN104144932A (zh) 2014-11-12
MX2014010684A (es) 2014-10-17
EP2822952A1 (en) 2015-01-14
WO2013134036A1 (en) 2013-09-12
CA2866671A1 (en) 2013-09-12
EA201491647A1 (ru) 2014-12-30
UY34666A (es) 2013-09-30
US8703953B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
TW201341387A (zh) 芳基醚結構之激酶抑制劑
KR102379518B1 (ko) 비아릴 키나제 억제제
EP3044226B1 (en) Aryl ether-base kinase inhibitors
US8901305B2 (en) Aryl lactam kinase inhibitors
US9932320B2 (en) Quinoline-based kinase inhibitors
AU2014315113B2 (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
US20150183791A1 (en) IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE
JP6276865B2 (ja) アリールラクタムキナーゼ阻害剤
US10174044B2 (en) Fused pyridines as kinase inhibitors
HK1217658B (zh) 基於吡唑并[1，5-a]嘧啶的化合物、包含其的组合物和其使用方法